These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 14578748)

  • 1. Use of candesartan cilexetil decreases proteinuria in renal transplant patients with chronic allograft dysfunction.
    Omoto K; Tanabe K; Tokumoto T; Shimmura H; Ishida H; Toma H
    Transplantation; 2003 Oct; 76(8):1170-4. PubMed ID: 14578748
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Candesartan improves blood pressure control and reduces proteinuria in renal transplant recipients: results from SECRET.
    Philipp T; Martinez F; Geiger H; Moulin B; Mourad G; Schmieder R; Lièvre M; Heemann U; Legendre C
    Nephrol Dial Transplant; 2010 Mar; 25(3):967-76. PubMed ID: 19887503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the effect of candesartan cilexetil on the steady-state pharmacokinetics of tacrolimus in renal transplant patients.
    Pietruck F; Kiel G; Birkel M; Stahlheber-Dilg B; Philipp T
    Biopharm Drug Dispos; 2005 May; 26(4):135-41. PubMed ID: 15768377
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term renoprotective effect of candesartan in renal transplant patients.
    Ishii T; Yasuda M; Itami Y; Hayashi T; Uemura H; Nose K; Nishioka T
    Transplant Proc; 2012 Apr; 44(3):638-41. PubMed ID: 22483458
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Change from ACE inhibitor, Ca-antagonist or beta-blocker to candesartan cilexetil: better efficacy and tolerance. SWITCH study (German study segment)].
    Baumgart P; Reismann J; Pohlmeyer H; Düsing R
    Dtsch Med Wochenschr; 2001 May; 126(19):547-50. PubMed ID: 11402910
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Candesartan cilexetil effectively reduces blood pressure in hypertensive children.
    Franks AM; O'Brien CE; Stowe CD; Wells TG; Gardner SF
    Ann Pharmacother; 2008 Oct; 42(10):1388-95. PubMed ID: 18664605
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The efficacy and tolerability of candesartan cilexetil in an elderly hypertensive population.
    McInnes GT; O'Kane KP; Jonker J; Roth J
    J Hum Hypertens; 1997 Sep; 11 Suppl 2():S75-80. PubMed ID: 9331015
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of 10-mg azilsartan compared with 8-mg candesartan cilexetil in Japanese patients with hypertension: a randomized crossover non-inferiority trial.
    Takahara M; Shiraiwa T; Shindo M; Arai A; Kusuda Y; Katakami N; Kaneto H; Matsuoka TA; Shimomura I
    Hypertens Res; 2014 Sep; 37(9):852-7. PubMed ID: 24739538
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of plasminogen activator inhibitor-1 by angiotensin II receptor blockers on cyclosporine-treated renal allograft recipients.
    Ishikawa A; Ohta N; Ozono S; Kawabe K; Kitamura T
    Transplant Proc; 2005 Mar; 37(2):994-6. PubMed ID: 15848601
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy, safety and pharmacokinetics of candesartan cilexetil in hypertensive children from 1 to less than 6 years of age.
    Schaefer F; van de Walle J; Zurowska A; Gimpel C; van Hoeck K; Drozdz D; Montini G; Bagdasorova IV; Sorof J; Sugg J; Teng R; Hainer JW;
    J Hypertens; 2010 May; 28(5):1083-90. PubMed ID: 20160654
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preserving target-organ function with candesartan cilexetil in patients with hypertension.
    Zannad F
    Blood Press Suppl; 2000; 1():36-9. PubMed ID: 11059635
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Beneficial action of candesartan cilexetil plus amlodipine or ACE inhibitors in chronic nondiabetic renal disease.
    Homma K; Hayashi K; Kanda T; Yoshioka K; Takamatsu I; Tatematsu S; Kumagai H; Wakino S; Saruta T
    J Hum Hypertens; 2004 Dec; 18(12):879-84. PubMed ID: 15295613
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiproteinuric effect of candesartan cilexetil in patients with chronic glomerulonephritis.
    Kurokawa K; Abe K; Saruta T; Arakawa M; Kikkawa R; Ueda N; Onoyama K; Tomita K; Ogawa N
    J Renin Angiotensin Aldosterone Syst; 2002 Sep; 3(3):167-75. PubMed ID: 12563567
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disparate systemic and renal blocking properties of angiotensin II antagonists during exogenous angiotensin II administration: implications for treatment.
    Willemsen JM; Rabelink TJ; Boer P; Gaillard CA
    J Hum Hypertens; 2004 Dec; 18(12):857-63. PubMed ID: 15361886
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of angiotensin-converting enzyme inhibitor, angiotensin II receptor antagonist and calcium antagonist on urinary podocytes in patients with IgA nephropathy.
    Nakamura T; Ushiyama C; Suzuki S; Hara M; Shimada N; Sekizuka K; Ebihara I; Koide H
    Am J Nephrol; 2000; 20(5):373-9. PubMed ID: 11092994
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Renal protective effect in hypertensive patients: the high doses of angiotensin II receptor blocker (HARB) study.
    Ohishi M; Takagi T; Ito N; Tatara Y; Hayashi N; Shiota A; Iwamoto Y; Katsuya T; Rakugi H; Ogihara T
    Hypertens Res; 2007 Dec; 30(12):1187-92. PubMed ID: 18344623
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Add-on angiotensin receptor blocker in patients who have proteinuric chronic kidney diseases and are treated with angiotensin-converting enzyme inhibitors.
    Kanno Y; Takenaka T; Nakamura T; Suzuki H
    Clin J Am Soc Nephrol; 2006 Jul; 1(4):730-7. PubMed ID: 17699280
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Additive antiproteinuric effect of angiotensin II receptor antagonist and angiotensin-converting enzyme inhibitor in patients with chronic glomerulonephritis].
    Iimura O; Kusano E; Tanba K; Yanagiba S; Amemiya M; Ando Y; Honma S; Muto S; Asano Y
    Nihon Jinzo Gakkai Shi; 2003 Jul; 45(5):439-44. PubMed ID: 14509219
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of candesartan cilexetil (TCV-116) in rats with chronic renal failure.
    Noda M; Matsuo T; Fukuda R; Ohta M; Nagano H; Shibouta Y; Naka T; Nishikawa K; Imura Y
    Kidney Int; 1999 Sep; 56(3):898-909. PubMed ID: 10469358
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acute and 3-month treatment effects of candesartan cilexetil on hemodynamics, neurohormones, and clinical symptoms in patients with congestive heart failure.
    Mitrovic V; Willenbrock R; Miric M; Seferovic P; Spinar J; Dabrowski M; Kiowski W; Marks DS; Alegria E; Dukát A; Lenz K; Arens HA
    Am Heart J; 2003 Mar; 145(3):E14. PubMed ID: 12660683
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.